Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-α, to induce apoptosis in Jurkat T cells: Possible mechanisms for immune escape by head and neck cancers

Oral Oncology

Volumn 44, Issue 7, 2008, Pages 672-682

  Kassouf, Nick ^a   Thornhill, Martin H ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Apoptosis; CAL27; Fas L; Head and neck cancer; IFN ; Jurkat; MCF 7; Oral cancer; T cells; TNF ; TR146; TRAIL

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; JURKAT CELLS; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45249087021     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.08.013     Document Type: Article

References (37)

1. Cohen J.J., Duke R.C., Fadok V.A., and Sellins K.S. Apoptosis and programmed cell death in immunity. Annu Rev Immunol 10 (1992) 267-293
2. Nagata S., and Golstein P. The Fas death factor. Science 267 5203 (1995) 1449-1456
3. Maimone M.M., Morrison L.A., Braciale V.L., and Braciale T.J. Features of target cell lysis by class I and class II MHC-restricted cytolytic T lymphocytes. J Immunol 137 11 (1986) 3639-3643
4. De Panfilis G. Alterations in molecular killing mechanisms: implications in skin disease. Br J Dermatol 145 6 (2001) 868-876
5. Nagata S. Apoptosis by death factor. Cell 88 3 (1997) 355-365
6. O'Reilly L.A., and Strasser A. Apoptosis and autoimmune disease. Inflamm Res 48 1 (1999) 5-21
7. French L.E., and Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 12 1 (2002) 51-55
8. O'Connell J., O'Sullivan G.C., Collins J.K., and Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184 3 (1996) 1075-1082
9. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., and Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20 1 (1999) 46-52
10. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., and Shanahan F. Fas counter-attack - the best form of tumor defense?. Nat Med 5 3 (1999) 267-268
11. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., Roche D., Collins J.K., et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160 11 (1998) 5669-5675
12. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274 5291 (1996) 1363-1366
13. Muschen M., Moers C., Warskulat U., Even J., Niederacher D., and Beckmann M.W. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99 1 (2000) 69-77
14. Naujokat C., Sezer O., and Possinger K. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells. Biochem Biophys Res Commun 264 3 (1999) 813-819
15. Oyaizu N., Kayagaki N., Yagita H., Pahwa S., and Ikawa Y. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem Biophys Res Commun 238 2 (1997) 670-675
16. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., et al. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57 3 (1994) 371-377
17. Fujita M., Goto K., Yoshida K., Okamura H., Morimoto H., Kito S., et al. Okadaic acid stimulates expression of Fas receptor and Fas ligand by activation of nuclear factor kappa-B in human oral squamous carcinoma cells. Oral Oncol 40 2 (2004) 199-206
18. Goto K., Fukuda J., and Haneji T. Okadaic acid stimulates apoptosis through expression of Fas receptor and Fas ligand in human oral squamous carcinoma cells. Oral Oncol 38 1 (2002) 16-22
19. Mishima K., Nariai Y., and Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression. Int J Cancer 105 5 (2003) 593-600
20. Ravindranath N.M., Nishimoto K., Chu K., and Shuler C. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy. Anticancer Res 20 1A (2000) 21-26
21. Kok S.H., Cheng S.J., Hong C.Y., Lee J.J., Lin S.K., Kuo Y.S., et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 217 1 (2005) 43-52
22. Inoue H., Shiraki K., Yamanaka T., Ohmori S., Sakai T., Deguchi M., et al. Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab Invest 82 9 (2002) 1111-1119
23. Gastman B.R., Atarshi Y., Reichert T.E., Saito T., Balkir L., Rabinowich H., et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 59 20 (1999) 5356-5364
24. Fukuda M., Hamao A., Tanaka A., Kitada M., Suzuki S., Kusama K., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity. Oncol Rep 10 5 (2003) 1113-1119
25. Knerer B., Hulla W., Martinek H., Formanek M., Temmel A., and Kornfehl J. IL-1 and TNF-alpha but no IL-2 expression is found in squamous cell carcinomas of the head and neck by RT-PCR. Acta Otolaryngol 116 1 (1996) 132-136
26. Nakano Y., Kobayashi W., Sugai S., Kimura H., and Yagihashi S. Expression of tumor necrosis factor-alpha and interleukin-6 in oral squamous cell carcinoma. Jpn J Cancer Res 90 8 (1999) 858-866
27. Younes F., Quartey E.L., Kiguwa S., and Partridge M. Expression of TNF and the 55-kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral Dis 2 1 (1996) 25-31
28. Shiraki K., Yamanaka T., Inoue H., Kawakita T., Enokimura N., Okano H., et al. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 26 5 (2005) 1273-1281
29. Ebert E.C. Interleukin-12 up-regulates perforin- and Fas-mediated lymphokine-activated killer activity by intestinal intraepithelial lymphocytes. Clin Exp Immunol 138 2 (2004) 259-265
30. Gisslinger H., Kurzrock R., Gisslinger B., Jiang S., Li S., Virgolini I., et al. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood 97 9 (2001) 2791-2797
31. Badie B., Schartner J., Vorpahl J., and Preston K. Interferon-gamma induces apoptosis and augments the expression of Fas and Fas ligand by microglia in vitro. Exp Neurol 162 2 (2000) 290-296
32. Bonetti B., Valdo P., Ossi G., De Toni L., Masotto B., Marconi S., et al. T-cell cytotoxicity of human Schwann cells: TNFalpha promotes FasL-mediated apoptosis and IFN gamma perforin-mediated lysis. Glia 43 2 (2003) 141-148
33. Xu X., Fu X.Y., Plate J., and Chong A.S. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 58 13 (1998) 2832-2837
34. Daniel P.T., and Krammer P.H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 152 12 (1994) 5624-5632
35. Chappell D.B., Zaks T.Z., Rosenberg S.A., and Restifo N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59 1 (1999) 59-62
36. Smith D., Sieg S., and Kaplan D. Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 160 9 (1998) 4159-4160
37. Young M.R., Wright M.A., Lozano Y., Matthews J.P., Benefield J., and Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 67 3 (1996) 333-338